A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer

CF33-hNIS-anti-PD-L1 is an oncolytic chimeric poxvirus encoding two transgenes: human sodium iodide symporter and a single-chain variable fragment against PD-L1. Comprehensive preclinical pharmacology studies encompassing primary and secondary pharmacodynamics and biodistribution and safety studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaurasiya, Shyambabu, Yang, Annie, Zhang, Zhifang, Lu, Jianming, Valencia, Hannah, Kim, Sang-In, Woo, Yanghee, Warner, Suanne G., Olafsen, Tove, Zhao, Yuqi, Wu, Xiwei, Fein, Seymour, Cheng, Linda, Cheng, Maria, Ede, Nicholas, Fong, Yuman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718831/
https://www.ncbi.nlm.nih.gov/pubmed/35024377
http://dx.doi.org/10.1016/j.omtm.2021.12.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718831/
https://www.ncbi.nlm.nih.gov/pubmed/35024377
http://dx.doi.org/10.1016/j.omtm.2021.12.002

Ejemplares similares